Get the Stockscreener App
120.87
0.70%
-0.85
After Hours:
119.02
-1.85
-1.53%
Genedx Holdings Corp stock is traded at $120.87, with a volume of 546.59K.
It is down -0.70% in the last 24 hours and down -2.48% over the past month.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
See More
Previous Close:
$121.72
Open:
$126.82
24h Volume:
546.59K
Relative Volume:
0.79
Market Cap:
$3.47B
Revenue:
$267.23M
Net Income/Loss:
$-83.50M
P/E Ratio:
-38.86
EPS:
-3.11
Net Cash Flow:
$-59.99M
1W Performance:
+0.57%
1M Performance:
-2.48%
6M Performance:
+25.09%
1Y Performance:
+101.45%
1-Day Range:
$117.37
$126.82
1-Week Range:
$117.37
$132.00
52-Week Range:
$54.14
$136.00
Genedx Holdings Corp Stock (WGS) Company Profile
Name
Genedx Holdings Corp
Sector
Industry
Phone
888-729-1206
Address
333 LUDLOW STREET, STAMFORD
Compare WGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
120.87 | 3.50B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-15-25 | Initiated | Guggenheim | Buy |
| May-09-25 | Upgrade | Jefferies | Hold → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-10-24 | Initiated | Craig Hallum | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
View All
Genedx Holdings Corp Stock (WGS) Latest News
Is GeneDx Holdings Corp. Equity Warrant still worth holding after the dipTrade Analysis Report & Long-Term Safe Return Strategies - newser.com
Will GeneDx Holdings Corp. stock maintain growth storyJuly 2025 Setups & Fast Entry Momentum Trade Alerts - newser.com
Using data filters to optimize entry into GeneDx Holdings Corp. Equity WarrantDividend Hike & Smart Allocation Stock Reports - newser.com
Price action breakdown for GeneDx Holdings Corp.Quarterly Portfolio Summary & Expert Curated Trade Setup Alerts - newser.com
GeneDx Holdings Corp. stock daily chart insights2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
What indicators show strength in GeneDx Holdings Corp.Sell Signal & Reliable Price Action Trade Plans - newser.com
Developing predictive dashboards with GeneDx Holdings Corp. dataWeekly Stock Report & High Accuracy Trade Alerts - newser.com
100,000 Newborns Goal — GeneDx Joins Florida’s First State‑Backed Genomic Newborn Screening Pilot - Stock Titan
Is GeneDx Holdings Corp. stock a safe haven assetTrade Volume Summary & Growth Focused Investment Plans - newser.com
What data driven models say about GeneDx Holdings Corp.’s futureQuarterly Profit Review & Low Risk High Win Rate Stock Picks - newser.com
Legal Advantage Investments Inc. Boosts Holdings in GeneDx Holdings Corp. $WGS - MarketBeat
GeneDx Holdings Corp. Experiences Evaluation Revision Amid Strong Market Performance and Dynamics - Markets Mojo
Analyzing GeneDx Holdings Corp. with risk reward ratio chartsJuly 2025 Movers & Safe Capital Growth Trade Ideas - newser.com
Is it time to cut losses on GeneDx Holdings Corp.2025 Performance Recap & Consistent Income Trade Ideas - newser.com
Technical signs of recovery in GeneDx Holdings Corp. Equity Warrant2025 Price Momentum & Weekly Setup with ROI Potential - newser.com
Can volume confirm reversal in GeneDx Holdings Corp. Equity Warrant2025 Earnings Impact & Risk Controlled Daily Trade Plans - newser.com
Using Python tools to backtest GeneDx Holdings Corp. strategiesQuarterly Investment Review & Real-Time Market Sentiment Alerts - newser.com
Technical analysis overview for GeneDx Holdings Corp. stock2025 Big Picture & Accurate Entry and Exit Point Alerts - newser.com
Using RSI to spot recovery in GeneDx Holdings Corp.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Top chart patterns to watch in GeneDx Holdings Corp.2025 Institutional Moves & Growth Focused Entry Point Reports - newser.com
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics Annual Meeting - MarketScreener
Genedx to launch autism partnership program to expand access to exome and genome testing - MarketScreener
GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program - Yahoo Finance
What data driven models say about GeneDx Holdings Corp. Equity Warrant’s futureJuly 2025 Decliners & Community Consensus Picks - newser.com
Will GeneDx Holdings Corp. rebound enough to break evenDip Buying & Reliable Entry Point Alerts - newser.com
How to escape a deep drawdown in GeneDx Holdings Corp.Rate Hike & High Yield Equity Trading Tips - newser.com
GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting - BioSpace
GeneDx's (WGS) Sell (D) Rating Reaffirmed at Weiss Ratings - MarketBeat
GeneDx Holdings Corp. $WGS Stake Trimmed by Gagnon Securities LLC - MarketBeat
GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025 - Business Wire
Q3 2025 Results: GeneDx to Release Financials Before Market Open; Investor Webcast and Conference Call - Stock Titan
Slow Capital Inc. Makes New Investment in GeneDx Holdings Corp. $WGS - MarketBeat
How to integrate GeneDx Holdings Corp. Equity Warrant into portfolio analysis tools2025 Price Momentum & Expert Approved Trade Ideas - newser.com
Is GeneDx Holdings Corp. stock ready for breakoutIPO Watch & Reliable Intraday Trade Plans - newser.com
Tools to monitor GeneDx Holdings Corp. recovery probability2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
Assessing GeneDx (WGS) Valuation Following BEACONS Launch and NIH-Backed Expansion in Newborn Genomics - simplywall.st
Evaluating GeneDx Holdings Corp. Equity Warrant with trendline analysisMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
Is GeneDx Holdings Corp. Equity Warrant stock positioned for long term growthOptions Play & Reliable Entry Point Trade Alerts - newser.com
What machine learning models say about GeneDx Holdings Corp. Equity WarrantQuarterly Performance Summary & Accurate Technical Buy Alerts - newser.com
Detecting price anomalies in GeneDx Holdings Corp. with AIWeekly Risk Report & Verified Entry Point Signals - newser.com
How to read the order book for GeneDx Holdings Corp.M&A Rumor & Risk Managed Investment Entry Signals - newser.com
What MACD signals say about GeneDx Holdings Corp. Equity WarrantPortfolio Return Summary & Daily Profit Focused Screening - newser.com
GeneDx (NASDAQ:WGS) Stock Rating Lowered by Zacks Research - MarketBeat
How Investors May Respond To GeneDx Holdings (WGS) Launching Nationwide Genomic Newborn Screening With NIH Support - simplywall.st
How the BEACONS Genomic Newborn Screening Initiative Could Shape GeneDx Holdings (WGS) Pediatric Genomics Leadership - simplywall.st
What’s next for GeneDx Holdings Corp. Equity Warrant stock priceJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Genedx Holdings Corp Stock (WGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genedx Holdings Corp Stock (WGS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 30 '25 |
Option Exercise |
32.67 |
1,246 |
40,707 |
10,001 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 30 '25 |
Sale |
108.38 |
6,609 |
716,261 |
3,392 |
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):